# Iongen Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iongen-therapeutics-co

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.iongentherapeutics.com
- Latest round: Angel (Sep 1, 2021)
- Investors on record: 2

## About

Established in 2021 and based in Nanjing, China, Iongen Therapeutics Co., Ltd. is an innovative biotechnology company specializing in the development of advanced pain management therapies, specifically focused on novel analgesics targeting sodium ion channels involved in pain perception. In January 2025, the company closed a pre-series A funding led by new investor Qiming Venture Partners. Iongen Therapeutics Co., Ltd. focuses on the research and development of innovative pain management therapies, specifically targeting the development of novel analgesics. The company's primary research centers on sodium ion channels Nav1.8 and Nav1.7. By targeting these channels, the company aims to create advanced pain relief solutions for various pain-related conditions.  The revenue model of Iongen Therapeutics Co., Ltd. is primarily structured around partnerships and collaborations within the pharmaceutical industry, focusing on B2B transactions. The company engages in agreements with healthcare providers and research institutions for the distribution and application of its analgesic products.  The company will use the pre-series A funding to invest in product research and development. The company plans to enhance its product pipeline by designing new analgesics targeting sodium ion channels with expected launches in the upcoming years. Additionally, Iongen aims to expand its market presence in Asia-Pacific regions by 2026, focusing on partnerships with local healthcare providers.

## Funding rounds

- Angel, Sep 1, 2021 — Huachuang Zhiye Capital, Nanjing Jiangbei New Area Sci-Tech Investment Group

## Investors

- Huachuang Zhiye Capital (https://capitalatlas.ai/funds/huachuang-zhiye-capital) — Angel
- Nanjing Jiangbei New Area Sci-Tech Investment Group — Angel